Biotage AB
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation produ… Read more
Biotage AB (BIOT) - Net Assets
Latest net assets as of March 2025: Skr3.85 Billion SEK
Based on the latest financial reports, Biotage AB (BIOT) has net assets worth Skr3.85 Billion SEK as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr4.71 Billion) and total liabilities (Skr862.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr3.85 Billion |
| % of Total Assets | 81.69% |
| Annual Growth Rate | 6.52% |
| 5-Year Change | 315.44% |
| 10-Year Change | 652.39% |
| Growth Volatility | 30.79 |
Biotage AB - Net Assets Trend (2000–2024)
This chart illustrates how Biotage AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biotage AB (2000–2024)
The table below shows the annual net assets of Biotage AB from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr4.11 Billion | +12.47% |
| 2023-12-31 | Skr3.66 Billion | +123.40% |
| 2022-12-31 | Skr1.64 Billion | +19.31% |
| 2021-12-31 | Skr1.37 Billion | +38.58% |
| 2020-12-31 | Skr990.04 Million | +13.08% |
| 2019-12-31 | Skr875.50 Million | +24.68% |
| 2018-12-31 | Skr702.18 Million | +15.37% |
| 2017-12-31 | Skr608.61 Million | +8.06% |
| 2016-12-31 | Skr563.24 Million | +3.03% |
| 2015-12-31 | Skr546.66 Million | +8.75% |
| 2014-12-31 | Skr502.65 Million | +5.43% |
| 2013-12-31 | Skr476.77 Million | -10.18% |
| 2012-12-31 | Skr530.83 Million | -5.86% |
| 2011-12-31 | Skr563.90 Million | -0.71% |
| 2010-12-31 | Skr567.95 Million | -47.85% |
| 2009-12-31 | Skr1.09 Billion | -3.18% |
| 2008-12-31 | Skr1.12 Billion | +41.26% |
| 2007-12-31 | Skr796.26 Million | +11.76% |
| 2006-12-31 | Skr712.47 Million | -3.49% |
| 2005-12-31 | Skr738.25 Million | +41.12% |
| 2004-12-31 | Skr523.13 Million | -14.17% |
| 2003-12-31 | Skr609.50 Million | -1.08% |
| 2002-12-31 | Skr616.16 Million | -21.51% |
| 2001-12-31 | Skr784.98 Million | -13.01% |
| 2000-12-31 | Skr902.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biotage AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 153700000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr1.54 Billion | 37.37% |
| Common Stock | Skr113.00 Million | 2.75% |
| Other Components | Skr2.46 Billion | 59.88% |
| Total Equity | Skr4.11 Billion | 100.00% |
Biotage AB Competitors by Market Cap
The table below lists competitors of Biotage AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangxi GETO New Materials Corporation Limited
SHE:300986
|
$787.39 Million |
|
C Sun Manufacturing Ltd
TW:2467
|
$787.59 Million |
|
International Petroleum Corporation
PINK:IPCFF
|
$787.64 Million |
|
Tronox Holdings PLC
NYSE:TROX
|
$787.83 Million |
|
Costamare Inc
NYSE:CMRE
|
$787.09 Million |
|
PVR INOX Ltd.
NSE:PVRINOX
|
$787.04 Million |
|
Cementos Pacasmayo S.A.A
F:EPCC
|
$786.60 Million |
|
Foxsemicon Integrated Technology Inc
TW:3413
|
$786.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotage AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,657,000,000 to 4,113,000,000, a change of 456,000,000 (12.5%).
- Net income of 284,000,000 contributed positively to equity growth.
- Dividend payments of 128,000,000 reduced retained earnings.
- Share repurchases of 2,000,000 reduced equity.
- New share issuances of 2,000,000 increased equity.
- Other comprehensive income increased equity by 124,000,000.
- Other factors increased equity by 176,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr284.00 Million | +6.9% |
| Dividends Paid | Skr128.00 Million | -3.11% |
| Share Repurchases | Skr2.00 Million | -0.05% |
| Share Issuances | Skr2.00 Million | +0.05% |
| Other Comprehensive Income | Skr124.00 Million | +3.01% |
| Other Changes | Skr176.00 Million | +4.28% |
| Total Change | Skr- | 12.47% |
Book Value vs Market Value Analysis
This analysis compares Biotage AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.43x to 2.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | Skr10.66 | Skr143.20 | x |
| 2003-12-31 | Skr10.55 | Skr143.20 | x |
| 2004-12-31 | Skr8.96 | Skr143.20 | x |
| 2005-12-31 | Skr10.46 | Skr143.20 | x |
| 2006-12-31 | Skr8.02 | Skr143.20 | x |
| 2007-12-31 | Skr8.95 | Skr143.20 | x |
| 2008-12-31 | Skr12.71 | Skr143.20 | x |
| 2009-12-31 | Skr12.34 | Skr143.20 | x |
| 2010-12-31 | Skr6.80 | Skr143.20 | x |
| 2011-12-31 | Skr7.22 | Skr143.20 | x |
| 2012-12-31 | Skr7.25 | Skr143.20 | x |
| 2013-12-31 | Skr7.00 | Skr143.20 | x |
| 2014-12-31 | Skr7.77 | Skr143.20 | x |
| 2015-12-31 | Skr8.45 | Skr143.20 | x |
| 2016-12-31 | Skr8.70 | Skr143.20 | x |
| 2017-12-31 | Skr9.40 | Skr143.20 | x |
| 2018-12-31 | Skr10.85 | Skr143.20 | x |
| 2019-12-31 | Skr13.43 | Skr143.20 | x |
| 2020-12-31 | Skr15.18 | Skr143.20 | x |
| 2021-12-31 | Skr20.96 | Skr143.20 | x |
| 2022-12-31 | Skr24.73 | Skr143.20 | x |
| 2023-12-31 | Skr49.42 | Skr143.20 | x |
| 2024-12-31 | Skr51.35 | Skr143.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotage AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.90%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.81%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.24x
- Recent ROE (6.90%) is above the historical average (2.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -27.33% | -172.55% | 0.14x | 1.10x | Skr-229.99 Million |
| 2003 | -40.10% | -140.74% | 0.21x | 1.36x | Skr-305.35 Million |
| 2004 | -21.99% | -31.37% | 0.53x | 1.33x | Skr-167.33 Million |
| 2005 | -5.40% | -9.27% | 0.44x | 1.32x | Skr-113.72 Million |
| 2006 | 0.40% | 0.54% | 0.57x | 1.29x | Skr-68.43 Million |
| 2007 | 12.48% | 20.02% | 0.50x | 1.24x | Skr19.75 Million |
| 2008 | 26.59% | 77.62% | 0.30x | 1.15x | Skr186.57 Million |
| 2009 | 1.24% | 3.42% | 0.32x | 1.13x | Skr-95.42 Million |
| 2010 | -72.23% | -95.64% | 0.62x | 1.22x | Skr-467.04 Million |
| 2011 | 5.76% | 7.58% | 0.61x | 1.24x | Skr-23.91 Million |
| 2012 | 7.22% | 8.28% | 0.71x | 1.23x | Skr-14.75 Million |
| 2013 | 8.68% | 9.31% | 0.75x | 1.24x | Skr-6.29 Million |
| 2014 | 10.17% | 10.42% | 0.79x | 1.23x | Skr847.00K |
| 2015 | 13.40% | 12.00% | 0.91x | 1.22x | Skr18.59 Million |
| 2016 | 16.48% | 13.89% | 0.96x | 1.23x | Skr36.47 Million |
| 2017 | 22.80% | 18.55% | 0.99x | 1.24x | Skr77.89 Million |
| 2018 | 23.87% | 18.40% | 0.91x | 1.43x | Skr97.41 Million |
| 2019 | 21.34% | 16.96% | 0.82x | 1.53x | Skr99.27 Million |
| 2020 | 17.68% | 16.02% | 0.76x | 1.45x | Skr76.00 Million |
| 2021 | 14.94% | 16.64% | 0.62x | 1.45x | Skr67.80 Million |
| 2022 | 16.37% | 17.11% | 0.67x | 1.43x | Skr104.30 Million |
| 2023 | 6.73% | 13.21% | 0.38x | 1.35x | Skr-119.70 Million |
| 2024 | 6.90% | 13.81% | 0.40x | 1.24x | Skr-127.30 Million |
Industry Comparison
This section compares Biotage AB's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $145,250,950
- Average return on equity (ROE) among peers: -24.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotage AB (BIOT) | Skr3.85 Billion | -27.33% | 0.22x | $787.18 Million |
| AddLife AB (publ) (ALIF-B) | $1.89 Billion | 27.39% | 1.20x | $1.41 Billion |
| Bonesupport Holding AB (BONEX) | $124.31 Million | -129.56% | 0.58x | $935.59 Million |
| Dynavox Group (DYVOX) | $210.60 Million | 23.08% | 5.28x | $777.82 Million |
| iZafe Group AB Series B (IZAFE-B) | $9.04 Million | -35.07% | 0.67x | $12.70 Million |
| Ortivus AB ser. A (ORTI-A) | $84.63 Million | -21.84% | 0.94x | $1.20 Million |
| S2Medical AB (S2M) | $25.11 Million | -73.41% | 0.22x | $641.00K |
| Stille AB (STIL) | $189.81 Million | 14.40% | 0.80x | $84.28 Million |
| Synsam AB (SYNSAM) | $-1.37 Billion | 0.00% | 0.00x | $726.29 Million |